Skip to main content

Table 2 Overall response

From: Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

 

all patients

patients receiving surgery

outcome

n = 32

n = 9

PD n (%)

21 (65.6)

3 (33.3)

PR n (%)

4 (12.5)

4 (44.4)

SD n (%)

7 (21.9)

2 (22.2)

  1. PR partial response; SD stable disease; PR progressive disease
  2. Response was assessed based on imaging (CT or MRI) scans in analogy to the RECIST v1.1. criteria
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us